Off-Label Use of Dalbavancin for Sequential Treatment of Spondylodiscitis by Methicillin-Resistant <i>Staphylococcus aureus</i>: A Retrospective Single-Centre Experience
<b>Background:</b> Our aim was to describe the clinical outcome and safety of the sequential treatment with off-label dalbavancin in patients with spondylodiscitis that is caused by methicillin-resistant <i>Staphylococcus aureus</i> (MRSA). <b>Methods</b>: We retrospectively included all patients >1...
Guardat en:
| Autors principals: | , , , , , , , |
|---|---|
| Format: | Artigo |
| Idioma: | Inglês |
| Publicat: |
MDPI AG
2022-10-01
|
| Col·lecció: | Antibiotics |
| Matèries: | |
| Accés en línia: | https://www.mdpi.com/2079-6382/11/10/1377 |
| Etiquetes: |
Sense etiquetes, Sigues el primer a etiquetar aquest registre!
|